Drugs / ANS-6637
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03831971 | Mar → Aug 2019 | substance-related disorder | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT03203499 | Feb → Nov 2017 | — | Amygdala Neurosciences, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04169360 | Jan 2021 | opiate dependence | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04311294 Comparator | Apr 2020 → Jan 2022 | alcohol-related disorders | University of California, Los Angeles | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03970109 Comparator | Oct 2019 → May 2020 | alcohol-related disorders | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANS-6637 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04311294 ↗ |
| Action | Inhibit | “an aldehyde dehydrogenase 2 (ALDH-2) inhibitor” NCT03831971 ↗ |
| Route | Oral | “Ascending single doses administered orally.” NCT03203499 ↗ |
| Target | ALDH2 | “an aldehyde dehydrogenase 2 (ALDH-2) inhibitor” NCT03831971 ↗ |